KI-Beratung Beta

  • Produktbild: Immunosuppression in Inflammatory Bowel Diseases
  • Produktbild: Immunosuppression in Inflammatory Bowel Diseases
Band 119

Immunosuppression in Inflammatory Bowel Diseases Standards, New Developments, Future Trends

Aus der Reihe Falk Symposium

189,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

The aetiology of the chronic inflammatory bowel diseases - Crohn's disease and ulcerative colitis - is still enigmatic. The therapeutic approach has therefore traditionally focused on anti-inflammatory principles, including corticosteroids and aminosalicylates. Since a significant proportion of patients...

Beschreibung

The aetiology of the chronic inflammatory bowel diseases - Crohn's disease and ulcerative colitis - is still enigmatic. The therapeutic approach has therefore traditionally focused on anti-inflammatory principles, including corticosteroids and aminosalicylates. Since a significant proportion of patients is steroid-dependent or refractory and because of the problematic side-effects of long-term systemic steroids, active immunosuppression has gained acceptance in the field.
The classical immunosuppressants azathioprine and 6-mercaptopurine have long been evidence-based in IBD, but underused. Recently, methotrexate and cyclosporine have also been proven to be effective in certain situations. Newer drugs like tacrolimus, mycophenolate and others may be similarly useful but their potential is still unclear. Finally, the immune modifiers including IL-10 and TNF-antibodies have been successfully subjected to controlled trials. Other experimental drugs discussed in this book are on the horizon.
This volume is the Proceedings of Falk Symposium 119 held in Freiburg-im-Breisgau, Germany, October 3-4, 2000, and covers systematically the field of immunosuppression in inflammatory bowel diseases. It is hoped that it will further the prudent use of these drugs in the proper clinical situations by increasing our understanding of both the mechanisms of action and the clinical benefit to the patient.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

30.06.2001

Abbildungen

XII, 260 p.

Herausgeber K. Fellermann + weitere

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

30.06.2001

Abbildungen

XII, 260 p.

Herausgeber
Verlag Springer Netherland
Seitenzahl

260

Maße (L/B/H)

24,1/16/2 cm

Gewicht

582 g

Auflage

2001 edition

Sprache

Englisch

ISBN

978-0-7923-8767-1

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Immunosuppression in Inflammatory Bowel Diseases
  • Produktbild: Immunosuppression in Inflammatory Bowel Diseases